Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

Summary

The goal of this clinical trial is to learn about the safety and effectiveness of ENV-294 in adults with moderate to severe atopic dermatitis. The main questions it will answer are: Is there an impact on the severity and area of atopic dermatitis when participants take ENV-294 What medical problems do participants have when taking ENV-294 Participants will: Take drug ENV-294 or a placebo once every day for 12 weeks Visit the clinic every 2 to 4 weeks for checkups and tests Keep a diary of their symptoms and when they took their study drug Return to the clinic for the final study visit at…

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Atopic Dermatitis (AD)

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

18 to 75 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Enveda Therapeutics

Last updated on ClinicalTrials.gov

September 25, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites